Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 5,325 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Continuous Dose Clear all

Conditions: Glioblastoma
Interventions: Lixumistat - Cohort 1, Lixumistat - Cohort 2; Drug
Lead sponsor: Macarena De La Fuente, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Kidney Transplant Failure and Rejection
Interventions: Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cholangiocarcinoma Cancer, Gallbladder Cancer, Pancreatic Cancer, Ampullary Cancer
Interventions: Gemcitabine, Docetaxel, Radiation; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obsessive-Compulsive Disorder
Interventions: Bitopertin, Placebo, SSRI; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more

Conditions: Solid Tumours
Interventions: GSK2126458; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 7
States / cities: San Francisco, California • New Brunswick, New Jersey • Chapel Hill, North Carolina + 4 more

Conditions: Myelodysplastic Syndrome, Leukemia
Interventions: Thymoglobulin, Busulfan, Fludarabine, Alloreactive NK Infusion, G-CSF, Tacrolimus, Methotrexate, Interleukin-2; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Lymphoma
Interventions: rituximab, vinorelbine ditartrate; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer
Interventions: Irinotecan, Cisplatin, Olaparib (for levels 1 and 5), Olaparib (for dose level 2), Mitomycin-C; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Paroxysmal Nocturnal Hemoglobinuria, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Relapsing Chronic Myelogenous Leukemia, Thrombocytopenia, Untreated Adult Acute Myeloid Leukemia
Interventions: bryostatin 1, sargramostim, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pediatric Obesity
Interventions: Topiramate, Phentermine; Drug
Lead sponsor: Janey Pratt; Other
Eligibility: 12 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Adrenoleukodystrophy (ALD), Krabbe Disease, Metachromatic Leukodystrophy (MLD), Sphingolipidoses, Peroxisomal Disorders
Interventions: Campath-1H, Cyclophosphamide, Busulfan, Allogeneic stem cell transplantation, Cyclosporine A, Mycophenolate Mofetil; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta 1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions: ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment); Dietary Supplement · Other
Lead sponsor: Arbor Life Labs; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment; Drug · Device · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Stem Cell Transplantation, Leukemia, Lymphoma
Interventions: Thiotepa, Clofarabine, Busulfan, Allogeneic Stem Cell Transplantation, Thymoglobulin (ATG), G-CSF (Filgrastim), Tacrolimus, Methotrexate, Cyclophosphamide, Mesna; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue, Autoimmune Enteropathy
Interventions: Withdrawal of Oral Budesonide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoma, Merkel Cell Carcinoma
Interventions: CRD3874; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Autism, Asperger's Syndrome, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder
Interventions: Cognitive-behavioral therapy, Treatment as Usual; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 7 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Cancer
Interventions: PF-04554878; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Cancer Of Prostate, Prostate Neoplasms
Interventions: PDS01ADC, Docetaxel, M7824, Prednisone, ADT; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years · Male only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Knee Osteoarthritis
Interventions: inulin, Maltodextrin (Placebo); Drug
Lead sponsor: Yale University; Other
Eligibility: 40 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Dravet Syndrome
Interventions: zorevunersen (STK-001); Drug
Lead sponsor: Stoke Therapeutics, Inc; Industry
Eligibility: 30 Months and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more

Search by objective public record fields.

Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

Dose-Escalation Study of GSK2126458

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

Medications After Adolescent Bariatric Surgery

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Budesonide in Patients With Immune Mediated Enteropathies

A Study of CRD3874-SI in People With Solid Tumors

Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders

A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome